UH Med Now
HIV AIDS: UH part of promising Mt. Sinai drug trial published in Science Translational Medicine
Pictured: Preparing for an injection. The drug studied in the HIV bowel study is delivered by injection.
By UH Med Now
The trial centered on the intestines, which researchers say are specifically targeted by HIV at the earliest stage of infection.
The study, though small, involved a drug already on the market for Crohn’s Disease and Irritable Bowel Syndrome and the lead researcher at New York’s Mount Sinai says it is a significant outcome.
“So I think if you have both HIV and inflammatory bowel disease then you should ask your physician about the possibility of going on this treatment which is anti alpha beta 7 therapy which is also known as vedolizumab or Entyvio,” said Dr. Saurabh Mehandru, MD, lead author of the research at Mt. Sinai Icahn School of Medicine:
UH John A. Burns School of Medicine (JABSOM) Tropical Medicine investigators Ivo N. SahBandar, Eun-young Park, Michael Corley and Lishomwa Ndhlovu helped analyze data for Mt. Sinai.
The drug trial results using venolizumab (sold by the brand name Entyvio) to counter HIV in the gut was published October 3, 2018 in the prestigious journal SCIENCE Translational Medicine.
The full interview video from lead scientists at Mt. Sinai is courtesy of the Icahn School of Medicine: